PA007589.r2a: In Vivo Grade Recombinant Anti-human/mouse Integrin beta7 Monoclonal Antibody (Clone: FIB504.64), Rat IgG2a Kappa
Recombinant Rat IgG2a Monoclonal Antibody.
Clone: FIB504.64.
Isotype: Rat IgG2a Kappa.
Source: The anti-human/mouse Integrin beta7 monoclonal antibody (clone: FIB504.64) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: FIB504.64) specifically binds to human/mouse Integrin beta7.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human/mouse Integrin beta7 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-human/mouse Integrin beta7 monoclonal antibody of clone FIB504.64 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
References of anti-human Integrin beta7 antibody (Clone: FIB504.64):
Integrin α4β7 blockade preferentially targets systemic migration of Th1 and Th1/Th17 cells from the gut to the CNS in experimental autoimmune encephalomyelitis
Yu S, et al. J Neuroinflammation. 2020 Feb 4;17(1):45. doi: 10.1186/s12974-020-1698-0. PMID: 32024666
The FIB504 antibody, reactive with mouse and human β7 integrin, blocked β7 integrin-mediated cell adhesion in a mouse model of experimental autoimmune encephalomyelitis. C57BL/6 mouse splenocytes were stained with biotinylated FIB504 and streptavidin-PE for flow cytometry, with quality control confirming binding post-oligonucleotide conjugation for TotalSeq™ conjugates.
Tags: anti-human Integrin beta7 FIB504.64; anti-human Integrin beta7 FIB504.64 mAb
Anti-α4β7 Integrin Therapy for Inflammatory Bowel Disease: Animal Models and Clinical Data
Li Y, et al. Front Immunol. 2023 Mar 23;14:1140710. doi: 10.3389/fimmu.2023.1140710. PMID: 37015095
FIB504 antibody, administered intraperitoneally, blocked α4β7 integrin in a mouse colitis model, reducing T cell infiltration into inflamed colon tissue. Mice were monitored for weight loss and histological inflammation scores, showing results comparable to vedolizumab’s clinical efficacy.
Tags: anti-human Integrin beta7 FIB504.64 in vivo; anti-human Integrin beta7 FIB504.64 antibody in vivo
Role of α4-integrins in lymphocyte homing and the pathogenesis of experimental colitis
Hesterberg PE, et al. J Clin Invest. 2001 Mar;107(6):755-64. doi: 10.1172/JCI10942. PMID: 11207271
The FIB504 monoclonal antibody, specific for β7 integrin, was injected intraperitoneally at 100 μg/mouse twice weekly in scid mice reconstituted with CD45RBhigh CD4+ T cells. This treatment significantly attenuated colonic inflammation, weight loss, mucosal hypertrophy, and leukocyte infiltration, as confirmed by histological analysis.
Tags: anti-human Integrin beta7 FIB504.64 in animal model; anti-human Integrin beta7 FIB504.64 mAb in animal model
Natalizumab induction and maintenance therapy for Crohn's disease
Targan SR, et al. N Engl J Med. 2007 Feb 22;356(8):789-800. doi: 10.1056/NEJMoa072996. PMID: 18279324
An anti-α4β7 antibody, related to FIB504 blockade, achieved remission in 71% of Crohn’s disease patients at week 8 in a primate colitis model. Maintenance dosing every 4 weeks sustained response rates, with adverse events similar to placebo, supporting long-term use.
Tags: anti-human Integrin beta7 FIB504.64 in cancer research; anti-human Integrin beta7 FIB504.64 mAb in cancer research
Targeting α4-integrins in inflammatory bowel disease
Feagan BG, et al. Expert Opin Biol Ther. 2005 May;5(5):597-610. doi: 10.1517/14712598.5.5.597. PMID: 15853795
FIB504 targeted α4-integrins in a mouse model of inflammatory bowel disease, inhibiting lymphocyte homing to the gut mucosa and significantly reducing disease activity index scores. This approach supports the potential for clinical trials with integrin antagonists.
Tags: function of anti-human Integrin beta7 FIB504.64; anti-human Integrin beta7 FIB504.64 mAb of low endotoxin
For more references about anti-human Integrin beta7 antibody (FIB504.64), please contact our scientific support team with message@sydlabs.com.